An Educational Tool for Improving Knowledge about Tumor Genetic Testing among Black or African American Men with Metastatic Prostate Cancer

Inclusion Criteria

• STAGE 1: Age 18-years-old or older
• STAGE 1: Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race, including Black or African-American, is included
• STAGE 1: Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed
• STAGE 1: Able to understand study procedures and to comply with them for the entire length of the study
• STAGE 1: Able to understand a written information sheet and willing to verbally consent
• STAGE 1: Fluent in English (reading, writing, and speaking)
• STAGE 2: Age 18-years-old or older
• STAGE 2: Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race, including Black or African American, is included
• STAGE 2: Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed
• STAGE 2: Able to understand study procedures and to comply with them for the entire length of the study
• STAGE 2: Fluent in English (reading, writing, and speaking)
• STAGE 2: Anticipated discussion of TGT within 0-365 days of enrollment, per treating oncology provider’s discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following: * Somatic DNA testing of already-collected tissue * Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure * Blood-based DNA testing to evaluate for circulating tumor DNA
• STAGE 2: Able to understand a written informed consent document and willing to sign it

Exclusion Criteria

• STAGE 1: Contraindication to any study-related procedure or assessment
• STAGE 2: Contraindication to any study-related procedure or assessment